Bavarian Nordic's MVA-BN® Vaccine Platform Selected by

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Feb 21, 2014 at 1:15 AM

Bavarian Nordic's MVA-BN® Vaccine Platform Selected by U.S. Department of Defense for New Vaccine Development

KVISTGAARD, Denmark, February 21, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that its MVA-BN vaccine platform technology has been selected by the Defense Threat Reduction Agency (DTRA), a part of the United States Department of Defense, for the development of a vaccine against two potential biological threats to national security - Burkholderia pseudomallei and Burkholderia mallei. "The award of this contract illustrates the strength of our MVA-BN vaccine platform technology, which has been developed through a decade-long partnership with the U.S. Department of Health and Human Services," said Anders Hedegaard, President and CEO of Bavarian Nordic. "As part of our strategy to expand our biodefense business beyond smallpox, we are pleased to add DTRA to our list of government partners with whom we work to develop novel biodefense vaccines." DTRA is the fourth U.S. Government agency to collaborate with Bavarian Nordic on the development of novel biodefense vaccines. Other ongoing collaborations include the development of vaccines against smallpox, filoviruses (Ebola and Marburg) and foot-and-mouth disease, for which the company has received funding from the Biomedical Advanced Research and Development Authority, the National Institute of Allergy and Infectious Diseases, and the Department of Homeland Security's Science and Technology Directorate. Under this new USD 0.5 million contract Bavarian Nordic will design, generate and test MVA-BN-based recombinant vaccines against Burkholderia. If the contract yields a successful proof of concept, DTRA may support further development of the vaccine through a larger contract award. Asger Aamund Chairman of the Board Contacts Anders Hedegaard, President & CEO. Phone +45 23 20 30 64 Paul Chaplin, President, Infectious Diseases Division. Phone 202-288-9220 About Burkholderia Burkholderia pseudomallei and Burkholderia mallei are bacterial pathogens that have been determined to pose a material threat sufficient to affect the United States' national security. B. pseudomallei causes melioidosis, a human disease endemic in Southeast Asia and northern Australia. B. mallei causes glanders, a zoonotic disease primarily occurring in Africa, Asia, the Middle East, and Central/South America. Because of the lengthy antibiotic therapy required to treat melioidosis and glanders, the suboptimal clinical outcomes, possible biothreat applications, and public health implications, there is significant interest in developing new vaccines capable of protecting against these agents, for which effective vaccines do not currently exist. About MVA-BN Platform Technology MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) is a robust and adaptable vaccine platform suitable for addressing a wide variety of infectious diseases. In addition to developing MVA-BN as a safer smallpox vaccine essential to protecting the immune-compromised population, Bavarian Nordic has conducted preclinical and clinical studies of recombinant MVA-BN-based vaccines for a variety of infectious diseases and numerous types of cancer. More than 7,300 individuals, nearly 1,000 of whom are immunocompromised, have been vaccinated with MVA-BN-based vaccines, showing the platform displays high immunogenicity and a favorable safety profile. About Bavarian Nordic Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. The vaccine is approved in Canada under the trade name IMVAMUNE and in the European Union under the trade name IMVANEX®. Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY. For more information, visit www.bavarian-nordic.com. This material is based upon work supported by the Defense Threat Reduction Agency under Contract No. HDTRA-1-14-C-0017. Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the Defense Threat Reduction Agency. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. [HUG#1763644]

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ensign Group Faces Lawsuit: Investors Weigh Options

Trouble Brewing for Ensign Group Investors There's no beating around the bush: The Ensign Group, Inc. (NASDAQ: ENSG) is caught up in a mess, and this isn't your run-of-the-mill kerfuffle. We've got a class action lawsuit on our hands, backed by the DJS Law Group. They’re not a bunch to take lightly; they’ve got experience with scalps in securities litigation. The...

Kuvings Unveils Hands-Free Juicer for Healthy Living

A Fresh Squeeze in the Juice World If you've ever wanted something that makes that morning juice without you running a marathon in your own kitchen, Kuvings might just have the answer with their new AUTO10 SQUARE™ Plus. Announced on October 30, 2026, this isn't just another fancy named gadget—it actually shakes things up with a hands-free design that’s tailored for...

Midterms and Retirement: Evaluate Precious Metals

Understanding the Financial Climate Amid Midterms Here we go, folks—the red, white, and blue circus we know as the midterms is back in town. And while politicians do their song and dance, you gotta ask yourself if your investments are strong enough to weather any storm those election winds might blow your way. American Independence Gold is waving the flag, telling folks...

Skechers Faces Shareholder Lawsuit: Must Act by Dec 21

Skechers Shareholders Stirring Over Lawsuit A fresh wave of legal antics is crashing at the shores of Skechers U.S.A., Inc. (NYSE: SKX) as frustrated shareholders mobilize against the footwear juggernaut. We're talking about a class action lawsuit here, folks, aimed at shaking down some clarity—or maybe just some cold, hard cash—from this bruiser over some sketchy...

Ball Corp to Steal the Spotlight at 2026 Baird Event

Ball Corporation's Big Moment at Baird 2026 Did you hear the rumble in the aluminum jungle? That's Ball Corporation (NYSE: BALL) gearing up to take the stage at the Baird 2026 Global Industrial Conference on November 12. The big wigs, Ron Lewis and Dan Rabbitt, CEO and CFO respectively, will throw down some serious wisdom at 7:55 a.m. Central Time. What'll they cover?...

ACR Poker's $650K Mystery PKO Tournaments Heat Up

Final Countdown for ACR Poker’s Halloween Bash When it comes to poker, there might not be a better mix of tension and thrill than a big bounty tournament, and ACR Poker’s $650K Halloween Special Mystery PKOs are right in the thick of it. We’re down to the wire with just the final starting flights left, and the action’s ready to blow the lid off come November 1....

Legal Bay's Year-End Cash Lifeline Amid Financial Strain

Legal Bay's Holiday Break for Plaintiffs Let's face it, waiting for a lawsuit to wrap up while bills stack up is about as comfortable as sitting on pins and needles. And smack in the middle of this drag, here come the holidays. Overspending on gifts, whopping travel costs, maybe some unexpected tuition bills—suddenly, the bank account's looking as bleak as a rainy...

FuelCell Energy Faces Legal Scrutiny After Stock Plunge

FuelCell Energy's Troubling Stock Dive FuelCell Energy's recent plummet isn't just a sobering reality for traders—it comes wrapped in controversy. With NASDAQ:FCEL suffering a 15.69% nosedive after revelations from their fiscal third-quarter results, the ticker’s future hangs precariously. Even for those who've braved the market’s caprices, seeing shares drop $2.68...

Abel Leads PRSA Maryland Chesapeake as New Chapter President

New Leadership and Opportunities in the PR Landscape Amid all the hustle and bustle of the corporate world, something big's brewing in Baltimore's public relations sphere. Greg Abel, the go-getting mastermind behind Abel Communications, has taken the helm of the newly formed PRSA Maryland Chesapeake chapter. This isn't just about shifting chairs or fancy titles—this...

Tiny Fish Revolutionizes Vertebrate Gene Studies

From Small Fish to Big Discoveries: Meet Danionella cerebrum Who would've thought a diminutive fish with a see-through body would give a jolt to the study of vertebrate genomes? Thanks to Danionella cerebrum, researchers at the Whitehead Institute have created the very first complete whole-body single-cell atlas of an adult vertebrate. Forget the Wall Street clamor for a...